U.S. markets open in 4 hours 18 minutes

  • S&P Futures

    4,541.50
    +5.00 (+0.11%)
     

  • Dow Futures

    35,565.00
    +8.00 (+0.02%)
     

  • Nasdaq Futures

    15,376.25
    +35.25 (+0.23%)
     

  • Russell 2000 Futures

    2,288.40
    -0.40 (-0.02%)
     

  • Crude Oil

    84.60
    +0.84 (+1.00%)
     

  • Gold

    1,803.90
    +7.60 (+0.42%)
     

  • Silver

    24.53
    +0.09 (+0.35%)
     

  • EUR/USD

    1.1648
    +0.0003 (+0.02%)
     

  • 10-Yr Bond

    1.6550
    0.0000 (0.00%)
     

  • Vix

    15.94
    +0.93 (+6.20%)
     

  • GBP/USD

    1.3775
    +0.0015 (+0.11%)
     

  • USD/JPY

    113.6210
    +0.1610 (+0.14%)
     

  • BTC-USD

    62,822.53
    +1,798.75 (+2.95%)
     

  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     

  • FTSE 100

    7,241.91
    +37.36 (+0.52%)
     

  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     
WATCH:

Yahoo Finance's 2021 All Markets Summit — The Path Forward

October 25 from 9:00 a.m to 5 p.m. ET

qPCR Instruments Market Size Worth $1.39 Billion By 2028: Grand View Research, Inc.

·6 min read

SAN FRANCISCO, Oct. 25, 2021 /PRNewswire/ -- The global qPCR instruments market size is expected to reach USD 1.39 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 3.4% from 2021 to 2028. The market is driven by the introduction of novel advanced products and an increase in demand for highly efficient diagnostic equipment.

Grand_View_Research_Logo
Grand_View_Research_Logo

The demand for qPCR instruments and consumables is being driven by the spike in the incidence of SARS-CoV-2 infections globally. The rise in the incidence is expected to add to the number of preventive screenings. This can be attributed to the fact that nations cannot determine the number of COVID-19 patients without screening them.

Key Insights & Findings:

  • By instrument, the GeneXpert segment is expected to exhibit the fastest CAGR from 2021 to 2028

  • Asia Pacific is expected to witness the fastest growth over the forecast period due to the increasing number of investments aimed at improving diagnostic infrastructure and the growing prevalence of infectious diseases

  • Unmet needs in the market are high. For instance, the lack of affordable qPCR instruments is keeping the market from reaching its full potential

  • Newly launched products such as QuantStudio 5 Dx Real-Time PCR System provide consumers with improved workflows and high-volume testing to provide faster results. Cost-effectiveness and software that are simplified give it additional advantages

  • North America captured the largest revenue share in 2020 and is expected to maintain its lead over the forecast period. Improving regulatory support and increasing launches of novel products are anticipated to fuel the market growth

Read 109 page market research report, "qPCR Instruments Market Size, Share & Trends Analysis Report By Instrument (GeneXpert, BioFireFilmArray Systems, BMS Mic System), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2021 - 2028", by Grand View Research

The miniaturization of three basic molecular assays is expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. These improvements are expected to improve the availability of POC molecular diagnostic tests to yield quick and effective test results. For instance, the Mic qPCR system by Biomolecular Systems weighs only 2 kilograms, making the device highly portable and easy to handle.

Newly launched products such as QuantStudio 5 Dx Real-Time PCR System provide consumers with improved workflows and high-volume testing to provide faster results. Cost-effectiveness and software that are simplified give it additional advantages. Furthermore, the approval of the instrument in over 50 countries can help strengthen the market growth. The instrument is also equipped with measures for research companion diagnostics, giving it a competitive edge.

The market has a high threat of external substitutes owing to the presence of digital PCR instruments that are highly advanced and more accurate. The strong threat of internal substitution can be attributed to the presence of numerous products available in the market. However, the higher price of these instruments is anticipated to reduce the overall threat, keeping it at a moderate level.

COVID-19 has increased opportunities for diagnostic devices. However, advanced PCR technologies, such as dPCR, are preferred more in developed economies as they can help reduce false-positive rates. The research on developing efficient qPCR instruments can reduce the threat of substitution of devices and improve market growth.

Over recent years, PCR has witnessed technological advancements in terms of sensitivity, accuracy, efficiency, and cost-effectiveness. Key players are introducing novel technologies to maintain a competitive edge.

Grand View Research has segmented the global qPCR instruments market based on instrument and region:

  • qPCR Instruments Outlook (Revenue, USD Million, 2017 - 2028)

  • qPCR Instruments Regional Outlook (Revenue, USD Million, 2017 - 2028)

Key Players of qPCR Instruments Market

  • Thermo Fisher Scientific, Inc.

  • F. Hoffmann-La Roche Ltd.

  • Bio-Rad Laboratories, Inc.

  • Danaher Corporation

  • Qiagen

  • Agilent Technologies, Inc.

  • Abbott

  • bioMerieux SA

  • Quantabio

  • Azure Biosystems, Inc.

  • Bio Molecular Systems

Check out more studies on topics related Real-time PCR, conducted by Grand View Research:

  • Real-time PCR & Digital PCR Market – The global Real-time PCR (qPCR) and Digital PCR (dPCR) market size were valued at USD 2.25 billion in 2018. It is expected to expand at a CAGR of 8.5% during the forecast period. High prevalence of target diseases and rapid technological advancements such as the development of high performance and superior qPCR and dPCR systems are expected to be the key factors driving the growth.

  • qPCR Assay Market – The global qPCR assay market is expected to grow during the forecast period due to increase intervention of the government with regards to funding for research and development activities coupled with rising R&D activities in proteomics and genomics along with advancement in technology.

  • Europe Real Time PCR Market – The European Real-time Polymerase Chain Reaction (qPCR) market was valued at over USD 182 million in 2014. Key drivers encouraging market growth include rising prevalence of infectious diseases, cancer, cardiometabolic disorders, and growing geriatric population base.

Browse through Grand View Research's coverage of the Global Clinical Diagnostics Industry

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/qpcr-instruments-market-size-worth-1-39-billion-by-2028-grand-view-research-inc-301407338.html

SOURCE Grand View Research, Inc.

Recommended Stories

  • 2 Biotech Stocks That Could Go Parabolic This Week

    The most recent examples are the explosive upward moves by shares of Donald Trump's social media-associated stocks, Digital World Acquisition (NASDAQ: DWAC) and Phunware (NASDAQ: PHUN). Last week, Digital World Acquisition's shares rose by as much as 1,500%. Mergers and acquisitions have been the name of the game for biotech investors this year.

  • Alibaba Has Lost $344 Billion in World's Biggest Wipeout

    (Bloomberg) -- Few people could have predicted the downward spiral for Alibaba Group Holding, when founder Jack Ma delivered a blunt criticism of China’s financial system last October. Most Read from BloombergCities' Answer to Sprawl? Go Wild.Hamburg Is at the Heart of Germany’s Growing Dilemma Over ChinaWhy Americans and Britons Are Rushing to Buy Idyllic Homes in ItalyOne of California’s Wealthiest Counties Could Run Out of Water Next SummerThe Top Money Maker at Deutsche Bank Reaps Billions F

  • How Low Can Moderna Stock Go?

    Moderna (NASDAQ: MRNA) is no longer the seemingly invincible, high-flying stock that it once was. There are plenty of reasons why the vaccine stock has lost some of its mojo. To me, there's a much more important question to attempt to answer: How low can Moderna stock actually go?

  • 3 Dividend Stocks Under $10 With at Least 8% Dividend Yield

    Every investor wants to see his stocks pay off – or he wouldn’t be in the markets. But finding the right investment, the ‘one’ that will bring profits, no matter what direction the overall markets take, can sometimes be challenging. The two simplest courses of action an investor can take to ensure solid returns are based on common sense. The first is, to buy low and sell high. That is, find a cheap stock with sound fundamentals and good prospects for growth – and buy in to take advantage of the

  • Big Tech companies report earnings: What to know this week

    Investors' focus this week will be on earnings results, with some of the most heavily weighted companies in the S&P 500 poised to deliver their quarterly reports.

  • The Crash is an Opportunity for Snap Inc.'s (NYSE: SNAP) Insiders to Start Buying

    If a corporate boogeyman existed, explicitly designed to haunt the tech platforms reliant on advertisement revenues, it would be called "Policy Changes." Although Apple's iOS 14.5 update announced tracking transparency months ago, it took some time for its aftershock to hit the environment, as companies like Snap Inc. (NYSE: SNAP) saw the impact on the revenues.

  • Dow Jones Futures: Apple, Microsoft Lead 7 Key Earnings, Tesla Rolls Back FSD Beta; Will Trump Stock DWAC Keep Rising?

    Here's how to handle peak earnings week. Can Trump SPAC stock DWAC keep rising? Tesla rolls back FSD Beta 10.3.

  • Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?

    Biotech stocks are in a slump. Despite numerous wins in the high-profile areas of COVID-19 and cancer therapy, the industry has failed to excite investors this year -- as seen in the 12% year-to-date fall in the the bellwether SPDR S&P Biotech ETF. Risk-tolerant growth investors appear to be favoring other vehicles over biotech in 2021, such as the red-hot cryptocurrency Shiba Inu (CRYPTO: SHIB), electric-vehicle giant Tesla (NASDAQ: TSLA), and emerging social media plays such as Digital World Acquisition (NASDAQ: DWAC) and Phunware (NASDAQ: PHUN).

  • These Are The 5 Best Stocks To Buy And Watch Now

    Buying a stock is easy, but buying the right stock without a time-tested strategy is incredibly hard. So what are the best stocks to buy now or put on a watchlist?

  • Richard Pzena’s 9 New Stock Picks

    In this article, we discuss Richard Pzena’s 9 new stock picks. You can skip our comprehensive analysis of Pzena’s history, investment philosophy, and hedge fund performance, and go directly to Richard Pzena’s 5 New Stock Picks. Richard Pzena founded Pzena Investment Management in 1995, and he serves as the managing principal, co-chief investment officer, and […]

  • 2 Unstoppable Stocks to Buy in the Next Market Crash

    You're more likely to panic if you don't have a plan.

  • 3 Tech Stocks You Should Own This Earnings Season

    Earnings season is upon us and companies are now reporting on their late summer financial results in earnest. Stock prices can go wild during these periods as companies post figures that either beat or fall short of investor expectations. Three tech names that recently reported are IBM (NYSE: IBM), Duck Creek Technologies (NASDAQ: DCT), and Lam Research (NASDAQ: LRCX).

  • 3 Inflation-Proof Dividend Stocks Begging to Be Bought

    For the stock market, inflationary pressures have historically tended to be something of a mixed bag: Many companies struggle, while others put up a relatively strong performance and can even benefit from unusual economic and monetary dynamics. In order to put investors on the trail of stocks that could perform well in this age of elevated inflation, we put together a panel of Motley Fool contributors and tasked them with identifying top picks for riding out these uncertain times. Keith Noonan (Broadcom): Semiconductors make the world go round.

  • These 3 Stocks Are Up at Least 7,400%. Are They Still Buys?

    Simply put, many investors fear that a significant run-up in a stock price likely means they've already missed out on their best chance to realize sizable gains from that stock and simply move on. Unfortunately, considering a stock's price gains in a vacuum, rather than considering where it can go from here, may be one of the biggest mistakes an investor can make, causing them to miss out on potentially game-changing opportunities.

  • Investing $100,000 in These 3 Dividend Stocks Could Give You Annual Income of $7,700

    The closer you get to retirement, dividend income will rank higher among your investing objectives. Many dividend stocks won't provide all that much income each year. Investing $100,000 spread across these three dividend stocks could give you added income of close to $7,700 per year.

  • Earnings Season Is Here! 3 Great Growth Stocks to Buy Now

    Unlike last year, when investors were monitoring the extent of the COVID-19 pandemic and the benefits of a vaccine, this quarter is all about big picture macroeconomic factors. Inflation, interest rates, supply chain challenges, and labor shortages headline this quarter's list of important themes. Although these topics have their relevance over the short term, they shouldn't detract from a company's long-term growth trajectory.

  • 7 Companies That Raised Their Dividends This Week

    Albertsons, Crown Castle International, and American Electric Power were among the larger U.S. companies that declared dividend increases this week.

  • 3 Explosive Stocks to Buy Right Now

    When it comes to high-powered growth stocks, good things come to those who wait. Admittedly, not every growth story you back will pan out over the long term, but just a handful of big winners can have an outsize impact on your investing performance and deliver life-changing returns. Unity Software (NYSE: U) is a company that provides a development engine, visual assets, and support services that make it easy for users to create digital experiences.

  • PayPal says it is not pursuing Pinterest acquisition

    A source at that time told Reuters that PayPal had offered $70 per share, mostly in stock, for Pinterest. At the reported price, a deal would have been the biggest acquisition of a social media company, surpassing Microsoft Corp's $26.2 billion purchase of LinkedIn in 2016.

  • Got $5,000? 3 Stocks To Hold for the Next 20 Years

    Do you know the keys to succeed at investing in stocks? In a year when the stock markets have hit record highs, Brookfield Renewable Partners (NYSE: BEP)(NYSE: BEPC) shares have hugely disappointed investors. Brookfield Renewable is not only among the world's renewable-energy producers, but it's also well diversified, with strong presence in hydropower and a growing presence in solar and wind.